Mallinckrodt and Endo were both involved in the sale of opioid painkillers and faced litigation claiming that they played a ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Leerink Partners reiterated their market perform rating on shares of 2seventy bio (NASDAQ:TSVT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage ...

The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

2seventy bio makes the NASDAQ top percentage gainer list on acquisition news, currently trading at $4.9500, up 2.1500,gaining 76.7857% on volume of over 30 Million shares.

TSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb BMY. Per the terms of ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.